Aktis Oncology, Inc. Common stock (AKTS)

Aktis Oncology, Inc. Common stock (AKTS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $890M; returns 1 day -6.1%, 1 week +4.4%.

Aktis Oncology, Inc. (AKTS) is a clinical-stage biotechnology company focused on the development of novel radiopharmaceutical therapies for solid tumor cancers. The company utilizes a proprietary miniprotein radioconjugate platform designed to selectively deliver powerful alpha-emitting isotopes, primarily Actinium-225 ([225Ac]), directly to tumor targets.

Groups AKTS belongs to

• Recent IPOs
• Biotechnology
• Clinical Stage Biotech
• Oncology
• Cancer Therapeutics
• Clinical Stage Biopharma
• Healthcare
• Biopharmaceutical
• Life Sciences
• Clinical Stage

AKTS financial model: income statement, cash flow and balance sheet